SAB-142

About SAB BIO

SAB BIO is a private, pre-revenue biotech founded in 2018, advancing a novel therapeutic approach for Type 1 Diabetes. The company's pipeline is centered on SAB-142, a disease-modifying therapy intended to delay disease progression by modulating the autoimmune attack on pancreatic beta cells. Operating in the high-need autoimmune and diabetes space, SAB BIO represents an early-stage venture with a focused scientific strategy aimed at altering the course of T1D. Its progress is guided by an established leadership and clinical advisory board.

About SAB Biotherapeutics

SAB Biotherapeutics' mission is to leverage its proprietary DiversitAb™ platform to develop a new class of fully human polyclonal antibody therapeutics. Its key achievement is the creation of a validated, scalable production system using transgenic cattle, which has advanced multiple candidates into clinical trials, including a program for COVID-19. The company's strategy is to clinically validate its platform in autoimmune disease, starting with type 1 diabetes, and expand into other areas of high unmet need where polyclonal antibodies offer a differentiated therapeutic profile. As a public company, SAB is focused on executing its clinical milestones to demonstrate proof-of-concept and attract strategic partnerships.

Therapeutic Areas

Other Type 1 Diabetes Drugs